Immatics News and Activities

Immatics is a company listed under the stock ticker IMTX (DE).

Immatics has a direct presence in 2 countries.

View the org chart displaying its 52 main executives

Most searched biographies at Immatics

• Harpreet Singh, Chief Executive Officer and Director
• Heather Mason, Director
• Peter Chambré, Chairman of the Board

Popular executive movements at Immatics

• Andy Deig has joined the company as Senior Vice President, Finance  (posted on April 16 2026).
• Amie Krause has joined the company as Chief People Officer  (posted on October 28 2025).

Create your alert
to follow the executive moves at Immatics.

Immatics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Immatics

• Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer | Immatics N.V.
• Immatics Announces First Quarter 2022 Financial Results and Business Update | Immatics N.V.
• Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs | Immatics N.V.
• Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors | Immatics N.V.
• Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors | Immatics N.V.
• German Press Releases | Immatics N.V.
• Immatics Announces Full Year 2021 Financial Results and Corporate Update | Immatics N.V.
• Press Releases | Immatics N.V.
• Immatics Appoints Cedrik Britten as Chief Medical Officer - Immatics
• Immatics Appoints Thomas Ulmer as Chief Financial Officer - Immatics
• View more press releases Close

Social media about Immatics

• Immatics on Wikipedia, Google News & Yahoo Finance
• Immatics on LinkedIn, X (Twitter) & YouTube